BEIJING (Business Wire) - Pharmaron announced a strategic partnership with Merck Serono, the biopharmaceutical division of Merck KGaA, Germany. In the framework of this partnership, Pharmaron’s new campus in the Beijing Economic and Technological Development Area (BDA) will serve as home to Merck Serono’s China R&D Laboratory. The focus of this laboratory will be clinical bioanalysis and biomarker characterization, allowing for the identification of gene mutations among the Chinese population, early detection of disease processes, and development of personalized medicines for cancer and neurodegenerative diseases.
Pharmaron, a leading integrated CRO in the US and China with expertise from discovery to IND, recently completed the first phase of its new Beijing campus, which boasts over 600,000 ft2. This new campus houses Pharmaron’s elaborate drug discovery services area including chemistry, DMPK, biology, pharmacology and GLP Bioanalysis.
On August 31, 2011, Merck Serono and Pharmaron celebrated the opening ceremony of Merck Serono’s China R&D Laboratory as the beginning of this long-term collaboration between the two companies.
Dr. Boliang Lou, Pharmaron Chairman and CEO, spoke jubilantly of this strategic relationship with Merck Serono in China, “This is an important day in Pharmaron’s history. We have always envisioned building a new R&D campus and inviting the world’s top scientists to collaborate with Pharmaron. Together, with world-leading drug R&D companies, we will contribute to advance research against devastating diseases.” Dr. Lou also commented, “Today, this dream has come true. Through this unique partnership, we are providing Merck Serono with a favorable environment as well as qualified staff to lead their drug development programs for local and regional clinical trials against local diseases and unmet medical needs.”
Joining Dr. Lou and Pharmaron were senior Beijing government officials, including Deputy Mayor Mr. Zhongwen Gou, as well as a group of delegates from Merck Serono. The Merck Serono team was led by Dr. Stefan Oschmann, President of Merck Serono, Mr. Wayne Paterson, Executive Vice President of Emerging Markets of Merck Serono, Dr. Howard Sui, Managing Director of Merck Serono China, and Ms. Jenny Wu, Site Head and Chief Medical Officer of R&D of Merck Serono China.